Mesoblast Limited vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Mesoblast Limited trades at $16.34 (market cap $2.17B), while Direxion Daily Semiconductor Bull 3X Shares trades at $158.33. Which is the better fit depends on your goals.
| MESO | SOXL | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $20.96 | $300.77 |
52-Week Low | $12.88 | $23.99 |
Enterprise Value | $2.17B | — |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SOXL trades at $136.81, up 1.24% on the day, amid a bearish technical signal with 17 sell indicators versus 7 buy. The semiconductor sector faces volatility, with recent news highlighting AI-driven demand potential but also capital expenditure concerns from major holdings like TSMC. Support sits at $127, with resistance at $144, indicating a critical juncture for near-term price action.
The outlook remains cautious due to leveraged ETF decay risks and sector-wide headwinds, though AI infrastructure growth offers long-term opportunity. Investors face elevated volatility from semiconductor cycle swings and competitive pressures, requiring careful risk management given the fund's amplified exposure.
Trailing returns across standard periods
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →